Cardinal Health, Avid conduct trials on Alzheimer imaging agent

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Avid Radiopharmaceuticals and Cardinal Health are working together on the early diagnosis of Alzheimer's disease and are currently conducting Phase III clinical studies of Florbetapir F-18 for imaging amyloid plaques in Alzheimer's disease.

Florbetapir F-18 (also known as 18F AV-45 and Florbetapir) is a PET imaging agent to detect beta-amyloid plaque deposits in the brain, said the Philadelphia based Avid. The company said that more than 100 clinical centers and more than 700 patients have participated in the Phase III clinical trials to test whether Florbetapir F-18 can detect Alzheimer's disease in living patients.

Cardinal Health headquartered in Dublin, Ohio manufactures and delivers fluorine-18 (F-18), the raw material needed to create Florbetapir.